International Journal of Gynecological Cancer

Article	Citations
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma	870
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)	212
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer	165
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer	136
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer	82
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy	79
Clear cell carcinoma of the ovary: a clinical and molecular perspective	78
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*	71
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-1	63
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-b	58
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors	58
Human papillomavirus-independent cervical cancer	50
Management of pregnancy in women with cancer	48
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery	45
The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life	45
Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice	45
Uterine serous carcinoma: key advances and novel treatment approaches	44
Evaluating meaningful levels of financial toxicity in gynecologic cancers	43
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program	40
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment follo	39
Advances in immunotherapy for cervical cancer: recent developments and future directions	38
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification	37
Prognostic factors in patients with vulvar cancer: the VULCAN study	37
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001	37
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes	36

Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)	36
SUCCOR cone study: conization before radical hysterectomy	35
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer	35
European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and s	35
COVID-19 and gynecological cancer: a review of the published guidelines	34
Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial	34
Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective	33
Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management	32
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)	31
Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study – a multicentric analysis of predictors of failed mapping	31
Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media survey	30
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer	29
Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study	27
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix	27
Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer	27
Simple vaginal trachelectomy in women with early-stage low-risk cervical cancer who wish to preserve fertility: the new standard of care?	27
Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: a propensity-matched analysis	27
Fertility preservation in women with early-stage gynecologic cancer: optimizing oncologic and reproductive outcomes	26
Ultrastaging methods of sentinel lymph nodes in endometrial cancer – a systematic review	25
Imaging modalities in pregnant cancer patients	25
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial	25
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?	24
Measurement of tumor size in early cervical cancer: an ever-evolving paradigm	24
Survival after minimally invasive surgery in early cervical cancer: is the intra-uterine manipulator to blame?	24
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care	24
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis	24
Updates in the treatment of vaginal cancer	23
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer	23
Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review	23
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023	22
Palliative electrochemotherapy in primary or recurrent vulvar cancer	22
Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature	21
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)	21
Improving response to progestin treatment of low-grade endometrial cancer	21
Cost-effectiveness of robotic hysterectomy versus abdominal hysterectomy in early endometrial cancer	21
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020	20
Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010)	20
Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer	20
Health-related quality of life among cervical cancer patients in India	20
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian ca	19
Endometrial carcinosarcoma	19
Clinical patterns and genomic profiling of recurrent ‘ultra-low risk’ endometrial cancer	19
Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers	18
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the Eu	18
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovar	18
A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer	18
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study	18
Impact of hypoxia on cervical cancer outcomes	18
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)	17
A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy	17

Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva	17
The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review	17
Neoadjuvant chemotherapy followed by surgery in cervical cancer: past, present and future	17
Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers	17
Neoadjuvant chemotherapy prior to fertility-sparing surgery in cervical tumors larger than 2 cm: a systematic review on fertility and oncologic outcomes	17
Urinary diversion after pelvic exenteration for gynecologic malignancies	17
Transgender patients: considerations for routine gynecologic care and cancer screening	17
Fertility preservation in patients with BRCA mutations or Lynch syndrome	17
Oxidative damage and antioxidants in cervical cancer	17
Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis	17
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the E	16
Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)	16
Exploiting replicative stress in gynecological cancers as a therapeutic strategy	16
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma	15
Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy	15
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer	15
A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel	15
Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer	15
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study	15
Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis	15
Enhanced recovery after minimally invasive gynecologic oncology surgery to improve same day discharge: a quality improvement project	15
BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral	15
Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm	14
Refusal of surgery and survival outcomes in endometrial cancer	14
Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation	14
Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium	14
Immunotherapy in endometrial cancer	14
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)	14
Adjuvant chemoradiation associated with improved outcomes in patients with microsatellite instability-high advanced endometrial carcinoma	14
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 va	14
Asbestos and ovarian cancer: examining the historical evidence	14
Long-term quality of life outcomes of women treated for early-stage endometrial cancer	14
Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review	14
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study	14
Rare ovarian tumors: an update on diagnosis and treatment	13
Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy	13
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)	13
Proportions and incidence of locally advanced cervical cancer: a global systematic literature review	13
Prognostic value of lymphovascular space invasion in early-stage cervical cancer	13
Characterization of vaginal microbiota in Chinese women with cervical squamous intra-epithelial neoplasia	13
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma	13
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance	13
Cervical conization and lymph node assessment for early stage low-risk cervical cancer	13
The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma	12
Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia	12
Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers	12
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for plati	12
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions	12
The Capulana study: a prospective evaluation of cervical cancer screening using human papillomavirus testing in Mozambique	12
Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer	12
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma	12
Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer	12
Image-guided brachytherapy in cervical cancer including fractionation	12
Multidisciplinary personalized approach in the management of vulvar cancer – the Vul.Can Team experience	12
Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits	12
Gastric-type adenocarcinoma of the cervix in patients with Peutz-Jeghers syndrome: a systematic review of the literature with proposed screening guidelines	12
Oncologic and obstetric outcomes after simple conization for fertility-sparing surgery in FIGO 2018 stage IB1 cervical cancer	12
Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer	11
Fertility and pregnancy outcome in gestational trophoblastic disease	11
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?	11
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)	11
Psychosexual morbidity in women with ovarian cancer	11
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis	11
Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study	11
Multimodality adjuvant therapy and survival outcomes in stage I–IV uterine carcinosarcoma	11
Updates on cervical cancer prevention	11
Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial)	11
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer	11
Predictive role of serum cholesterol and triglycerides in cervical cancer survival	11
Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer	11
Comparison of laparoscopic versus open radical hysterectomy in patients with early-stage cervical cancer: a multicenter study in China	11
Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery	11
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEG	11
Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis	11
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer	11
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis	10
Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer	10
Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors	10
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected	10
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation	10

FIGO 2018 stage IB endocervical adenocarcinomas: an international study of outcomes informed by prognostic biomarkers	10
Incorporating molecular profiling into endometrial cancer management requires prospective studies	10
Race-driven survival differential in women diagnosed with endometrial cancers in the USA	10
The role of radiotherapy in ovarian cancer	10
Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program	10
Uterine transposition after radical trachelectomy	10
Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer	10
Quality assurance in human papillomavirus testing for primary cervical screening	10
The application of metabolomics in ovarian cancer management: a systematic review	10
Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER)	10
Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique	10
Physical activity trajectories following gynecological cancer: results from a prospective, longitudinal cohort study	10
The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety	9
Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study	9
Inside the war: life in Ukraine	9
COVID-19: gynecologic cancer surgery at a single center in Madrid	9
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer	9
Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America	9
Scaling up community-based cervical cancer screening in Cameroon employing a single visit approach	9
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline	9
Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer	9
Role of adjuvant therapy in stage IIIC2 endometrial cancer	9
Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study	9
The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries	9
Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking	9
Simplified anatomical nomenclature of lateral female pelvic spaces	9
Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study	9
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis	9
Fertility sparing surgery in sex-cord stromal tumors: oncological and reproductive outcomes	9
Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma	9
Uterine transposition for gynecological cancers	9
Comparison of laparoscopic and abdominal radical hysterectomy for early stage cervical cancer: oncologic outcomes based on tumor diameter	9
The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer	9
Detection of microRNA in urine to identify patients with endometrial cancer: a feasibility study	9
Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size <2 cm: a systematic review and meta-analysis	9
Sentinel lymph node biopsy alone in the management of early cervical carcinoma	9
COVID-19 global pandemic: options for management of gynecologic cancers. The experience in surgical management of ovarian cancer in the second highest affected Italian region	8
Pre-operative surgical algorithm: sentinel lymph node biopsy as predictor of parametrial involvement in early-stage cervical cancer	8
Metronomic oral cyclophosphamide in relapsed ovarian cancer	8
Avascular spaces in radical hysterectomy	8
Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators	8
Role of stereotactic body radiotherapy in gynecologic radiation oncology	8
Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)	8
Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review	8
Radiotherapy in Southern Italy at the time of COVID-19: options for radiation oncology units	8
Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study	8
Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer	8
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion	8
Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees	8
Endometrial stripe thickness: a preoperative marker to identify patients with endometrial intraepithelial neoplasia who may benefit from sentinel lymph node mapping and biopsy	8
Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer	8
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer	8
Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients	8
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)	8
Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002)	8
Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer	8
Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic	8
Biomarker-driven therapy in endometrial cancer	8
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer	7
Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation	7
Radical trachelectomy	7
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study	7
Palliative treatment with electrochemotherapy in recurrent or metastatic vaginal cancer	7
Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States	7
Radiotherapy dose escalation on pelvic lymph node control in patients with cervical cancer	7
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer,	7
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis	7
Primary mucinous ovarian cancer: options for surgery and chemotherapy	7
Nerve-sparing radical hysterectomy—Muallem technique with explanation of parametrium and paracolpium anatomy	7
Impact of surgical approach on prevalence of positive peritoneal cytology and lymph-vascular invasion in patients with early-stage endometrial carcinoma: a National Cancer Database study	7
Fertility considerations prior to conservative management of gynecologic cancers	7
Intracardiac intravenous leiomyomatosis: diagnosis and management	7
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose	7
Management of ovarian masses in pregnancy: patient selection for interventional treatment	7
Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis	7
Robotic uterine transposition for a cervical cancer patient with pelvic micrometastases after conization and pelvic lymphadenectomy	7
Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer	7
Integrating antibody drug conjugates in the management of gynecologic cancers	7
Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis	7
Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cer	7
Prediction scoring system based on clinicohematologic parameters for cervical cancer patients undergoing chemoradiation	7
Sentinel lymph node detection in early-stage ovarian cancer: a systematic review and meta-analysis	7
Patient-initiated follow-up for low-risk endometrial cancer: a cost-analysis evaluation	7
Real time quantitative methylation detection of PAX1 gene in cervical cancer screening	7
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3	7
Uterine transposition in a pre-pubertal patient	7
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial	7
Lymphadenectomy for early-stage mucinous ovarian carcinoma	7
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series	7
Disparity of ovarian cancer survival between urban and rural settings	7
Risk of second malignancy in patients with ovarian clear cell carcinoma	7
Laparoscopic aortic lymphadenectomy in left-sided inferior vena cava	6
Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups	6
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis	6
Transdiaphragmatic and transxiphoid cardiophrenic lymph node resection step-by-step in advanced ovarian cancer	6